TreatmentsJul 20, 2023
Community statement: BIOCAD
Biocad, a Russian biotechnology company, shares a community statement on its gene therapy product, ANB-004, which is being developed to treat SMA.
SMA Newsroom
TreatmentsJul 17, 2023
Community update from Biogen
We are pleased to share with you the latest community update issued by Biogen.
OtherJul 7, 2023
Community update from Roche
We are pleased to share with you the latest community update issued by Roche.
It contains the information shared at the Cure SMA Research & Clinical Care Meeting 2023 and Family Conference which took place last week.
Clinical trialsJun 30, 2023
Scholar Rock announces new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.
Scholar Rock announces new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.